Discussion
The experimental therapy barzolvolimab can reduce disease activity in people with chronic spontaneous urticaria (CSU) — an inflammatory disorder characterized by recurrent itching and hives — who experience angioedema, according to results from two Phase 3 clinical trials. Celldex Therapeutics, the company developing barzolvolimab, plans to use the…